Returning guest, Dr. Jeffrey Stark, MD, Head of Medical Immunology at UCB discusses the results from the BE RADIANT and BE SURE studies, comparing the efficacy and safety of bimekizumab to secukinumab and adalimumab, respectively, in the treatment of moderate to severe plaque psoriasis in adults. Both studies met all primary and ranked secondary endpoints.These data were published in the “New England Journal of Medicine” (April 2021).
Jeffrey Stark, MD, is the Head of Medical Immunology at UCB and is board-certified in both rheumatology and internal medicine. After completing training at Vanderbilt University and Emory University, he spent several years in full-time rheumatology practice in both private and academic clinical settings. In subsequent industry medical affairs roles, Dr. Stark has focused on medical education, advocacy, data generation, and highlighting the unmet needs of patients with immunologic diseases. In addition to his role at UCB, Dr. Stark serves as a board member of the American College of Rheumatology (ACR) Research Foundation and is a member of the Medical Advisory Board of the Georgia Chapter of the Lupus Foundation. Dr. Stark is also a past President of the Georgia Society of Rheumatology.